Integrated Multi-omics Analysis Identifies Diagnostic Biomarkers for Acute Coronary Syndrome in Type 2 Diabetes Mellitus Patients

ABSTRACT:

Biomarkers for the early identification of acute coronary syndrome (ACS) risk remain inadequately investigated, particularly in patients with type 2 diabetes mellitus (T2DM), for whom timely clinical intervention may substantially enhance prognostic outcomes. The gut microbiota and serum metabolites may serve as pivotal mediators in the occurrence and progression of ACS among patients with T2DM , and whether these factors can be used for the precise discrimination of patients with T2DM complicated by ACS remains to be elucidated. Overall, 76 participants were enrolled (38 patients diagnosed with T2DM complicated by ACS and another 38 with T2DM without ACS). 16S rRNA gene sequencing combined with untargeted LC-MS metabolomics revealed a dysregulated gut-serum axis in patients with T2DM complicated by ACS. We observed enrichment of Enterococcus spp. and Butyricimonas spp., alongside lipid metabolite dysregulation—specifically upregulation of PC(16:0/9:0(CHO)) and arachidonic acid versus downregulation of cholesterol sulfate. By integrating multi-omics data and applying various feature selection methods, we subsequently identified six key biomarkers. The final constructed combined model robustly distinguished patients with T2DM complicated by ACS from those with T2DM alone (AUC = 0.983), outperforming the other single-omics models. Our study revealed that the gut microbiota and related serum metabolites serve as key mediators in the onset and progression of ACS among patients with T2DM, and demonstrated their potential value as noninvasive biomarkers for the early diagnosis of T2DM complicated by ACS.

INSTRUMENT(S): Liquid Chromatography MS - positive, Liquid Chromatography MS - negative

PROVIDER: MTBLS14087 | MetaboLights | 2026-03-19

REPOSITORIES: MetaboLights